SYSTM Wealth Solutions LLC Boosts Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

SYSTM Wealth Solutions LLC lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,001 shares of the medical equipment provider’s stock after purchasing an additional 500 shares during the quarter. Intuitive Surgical accounts for about 1.1% of SYSTM Wealth Solutions LLC’s holdings, making the stock its 26th largest holding. SYSTM Wealth Solutions LLC’s holdings in Intuitive Surgical were worth $4,894,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ISRG. E Fund Management Co. Ltd. lifted its stake in shares of Intuitive Surgical by 0.8% in the 2nd quarter. E Fund Management Co. Ltd. now owns 3,973 shares of the medical equipment provider’s stock valued at $1,767,000 after acquiring an additional 33 shares during the last quarter. Wealth Alliance lifted its stake in shares of Intuitive Surgical by 2.7% in the 2nd quarter. Wealth Alliance now owns 2,796 shares of the medical equipment provider’s stock valued at $1,244,000 after acquiring an additional 74 shares during the last quarter. Bradley Foster & Sargent Inc. CT lifted its stake in shares of Intuitive Surgical by 7.0% in the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 40,099 shares of the medical equipment provider’s stock valued at $17,838,000 after acquiring an additional 2,627 shares during the last quarter. Mutual of America Capital Management LLC lifted its stake in shares of Intuitive Surgical by 5.6% in the 2nd quarter. Mutual of America Capital Management LLC now owns 48,905 shares of the medical equipment provider’s stock valued at $21,755,000 after acquiring an additional 2,605 shares during the last quarter. Finally, Cranbrook Wealth Management LLC bought a new stake in shares of Intuitive Surgical in the 2nd quarter valued at about $55,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $483.32 on Wednesday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.18. The firm has a market capitalization of $171.43 billion, a P/E ratio of 87.24, a P/E/G ratio of 5.41 and a beta of 1.39. The stock has a 50 day moving average price of $465.50 and a 200-day moving average price of $423.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 EPS. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $446.60, for a total value of $167,921.60. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,458,979.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Intuitive Surgical news, General Counsel Gary Loeb sold 300 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $475.00, for a total transaction of $142,500.00. Following the sale, the general counsel now directly owns 1,595 shares in the company, valued at approximately $757,625. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Robert Desantis sold 376 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $446.60, for a total value of $167,921.60. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,458,979.60. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock worth $25,528,753 in the last 90 days. Insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

ISRG has been the subject of a number of recent research reports. Citigroup boosted their target price on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. The Goldman Sachs Group assumed coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price for the company. Robert W. Baird upped their price target on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research report on Friday, July 19th. BTIG Research upped their price target on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Finally, Piper Sandler upped their price target on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $446.45.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.